Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 184

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3–ABCB1 Signaling in Hepatocellular Carcinoma

Open access
Hu, Beiyuan, Zou, Tiantian, Qin, Wei, Shen, Xiaotian, Su, Yinghan, Li, Jianhua, Chen, Yang, Zhang, Ze, Sun, Haoting, Zheng, Yan, Wang, Chao-Qun, Wang, Zhengxin, Li, Tian-En, Wang, Shun, Zhu, Le, Wang, Xufeng, Fu, Yan, Ren, Xudong, Dong, Qiongzhu, Qin, Lun-Xiu · 2022 · Cancer Research

Abstract

Lenvatinib is an inhibitor of multiple receptor tyrosine kinases that was recently authorized for first-line treatment of hepatocellular carcinoma (HCC). However, the clinical benefits derived from lenvatinib are limited, highlighting the urgent need to understand mechanisms of resistance. We report here that HCC cells develop resistance to lenvatinib by activating EGFR and stimulating the EGFR–STAT3–ABCB1 axis. Lenvatinib resistance was accompanied by aberrant cholesterol metabolism and lipid raft activation. ABCB1 was activated by EGFR in a lipid raft–dependent manner, which significantly enhanced the exocytosis of lenvatinib to mediate resistance. Furthermore, clinical specimens of HCC showed a correlation between the activation of the EGFR–STAT3–ABCB1 pathway and lenvatinib response. Erlotinib, an EGFR inhibitor that has also been shown to inhibit ABCB1, suppressed lenvatinib exocytosis, and combined treatment with lenvatinib and erlotinib demonstrated a significant synergistic effect on HCC both in vitro and in vivo. Taken together, these findings characterize a mechanism of resistance to a first-line treatment for HCC and offer a practical means to circumvent resistance and treat the disease. Significance: HCC cells acquire resistance to lenvatinib by activating the EGFR–STAT3–ABCB1 pathway, identifying combined treatment with erlotinib as a strategy to overcome acquired resistance and improve the clinical benefit of lenvatinib.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-21-4140

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 184

Metadata

Authors
Hu, B., Zou, T., Qin, W., Shen, X., Su, Y., Li, J., Chen, Y., Zhang, Z., Sun, H., Zheng, Y., Wang, C.-Q., Wang, Z., Li, T.-E., Wang, S., Zhu, L., Wang, X., Fu, Y., Ren, X., Dong, Q., & Qin, L.-X.
Venue
Cancer Research
Published
2022-09-06
Volume
82
Issue
20
Pages
3845-3857
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W4294785826
Cited by
184
References
9
FWCI
18.14
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3–ABCB1 Signaling in Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-21-4140
The paper
Hu, B., Zou, T., Qin, W., Shen, X., Su, Y., Li, J., Chen, Y., Zhang, Z., Sun, H., Zheng, Y., Wang, C.-Q., Wang, Z., Li, T.-E., Wang, S., Zhu, L., Wang, X., Fu, Y., Ren, X., Dong, Q., & Qin, L.-X. (2022). Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3–ABCB1 Signaling in Hepatocellular Carcinoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-21-4140

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.